North Carolina biotechnology company G-Zero Therapeutics aims to develop a pill that people can take to protect against the harmful effects of chemotherapy and radiation exposure. The Chapel Hill-based company now has a $3 million federal grant to advance its work.
G-Zero, a spinout from the University of North Carolina at Chapel Hill, received the $3 million grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The phase II Small Business Innovation Research Grant follows a $600,000 phase I grant awarded in 2009. Chief Science Officer Jay Strum said that the funding will allow G-Zero’s scientists to move its candidates through studies in preparation for an Investigational New Drug application.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
G-Zero Therapeutics has discovered a novel, small-molecule method to prevent hematological side effects of radiation and chemotherapy. The technology also protects the kidney. G-Zero is developing the technology to make “radiomitigants,” therapies that mitigate toxicity to bone marrow and bodily organs following exposure to radiation. A few drugs are currently available to decrease toxicity before radiation exposure, but there are no drugs to treat toxicity after exposure. In addition to healthcare applications, G-Zero said that the development of nontoxic radiomitigants is a top U.S. biodefense priority.
G-Zero was founded in 2008 with help from Carolina Kickstart, a program at UNC that works to turn university research into new companies. G-Zero co-founder Dr. Norman Sharpless, a professor of medicine and genetics at UNC’s school of medicine, describes G-Zero’s technology in greater detail in this company video: